Back to search
FDAFDA · Food and drugs·Recall number D-0511-2017

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Published March 15, 2017 · Recall initiated: February 17, 2017

Summary

FDA records drug Class III recall D-0511-2017, published March 15, 2017 and initiated February 17, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 25,916 cartons; Lot: Lot # 34025762A, Exp 06/17. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide in the United States and Puerto Rico
Lot
Lot # 34025762A, Exp 06/17
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454. recalled?

Yes. FDA published recall D-0511-2017 on March 15, 2017. Reported hazard: Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter